Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imaging.

Autor: Nowotnik DP, Canning LR, Cumming SA, Harrison RC, Higley B, Nechvatal G, Pickett RD, Piper IM, Bayne VJ, Forster AM, et. al.
Jazyk: angličtina
Zdroj: Nuclear medicine communications [Nucl Med Commun] 1985 Sep; Vol. 6 (9), pp. 499-506.
DOI: 10.1097/00006231-198509000-00002
Abstrakt: A new radiopharmaceutical, 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO) has shown considerable promise for single photon emission tomographic (SPECT) imaging of the brain. In animal biodistribution studies this complex demonstrates good brain uptake with prolonged retention of activity in brain. Further improvement of these properties, resulting in higher brain uptake with very slow washout and fixed regional distribution has been achieved following the isolation of the d,1-diastereoisomer of HM-PAO.
Databáze: MEDLINE